Lemme Purr Review

Index of Contents →

Share this article

Watch this on YouTube.

If you’ve been scrolling through wellness products online, chances are you’ve come across Lemme Purr, a gummy supplement that promises to support vaginal health. It’s part of a growing trend of gummy probiotics marketed for everything from gut balance to immune support. But what’s really inside these gummies—and can they actually deliver on their claims?

Gummy Probiotics and Stability

Here’s the deal: making probiotics into gummies isn’t as straightforward as it sounds. The process involves heat, moisture, and sugar—three factors that are notorious for killing off the delicate strains of bacteria most commonly used in traditional probiotic capsules. For example, Lactobacillus, a popular strain for vaginal health, has been shown to lose almost all of its potency within five days when stored in a gummy at warm room temperatures. Even under refrigeration, the majority of these bacteria die off within a month.

That’s why nearly every gummy probiotic on the market—including Lemme Purr—leans on just two specific strains: Bacillus coagulans and Bacillus subtilis. These are known as spore-forming probiotics, meaning they have a natural protective shell that helps them survive not just the gummy-making process, but also the trip through your digestive system. Research shows these strains can remain shelf-stable in gummy form for up to 24 months.

While some brands include additional strains, the reality is that those extra microbes are unlikely to survive long enough to make a difference by the time you actually take the supplement.

Ingredients

Bacillus coagulans

This is the star probiotic in Lemme Purr. It has been studied in a few small trials involving women being treated for bacterial vaginosis. Some participants reported slight improvements in symptoms while taking the probiotic—but here’s the catch: neither of those studies included a placebo group, making it hard to know whether the results were due to the probiotic or simply the act of taking something.

Where Bacillus coagulans really shines is in supporting digestive health. In one study, people with mild constipation who took just 1 billion CFUs daily saw improvements in regularity and comfort. Another study involving individuals with IBS (Irritable Bowel Syndrome) found that a daily dose of 2 billion CFUs reduced diarrhea, bloating, and even abdominal pain. Higher doses, around 6 billion CFUs daily, have also been linked to reductions in anxiety and headaches related to IBS.

Beyond digestion, the benefits of Bacillus coagulans are less clear. Some studies suggest it might slightly reduce cold symptoms in children, ease rheumatoid arthritis pain when paired with medications, or lower inflammation in people with non-alcoholic fatty liver disease (NAFLD). But strong, consistent evidence is still lacking—especially when it comes to vaginal health.

Pineapple Fruit Powder

Lemme Purr also includes pineapple fruit powder, likely added for its bromelain content. Bromelain is a natural enzyme in pineapple that helps break down proteins and is sometimes used topically for its anti-inflammatory and antibacterial properties. However, when consumed orally, there’s no solid evidence that bromelain—or pineapple itself—has any effect on vaginal health.

Are Oral Probiotics Effective for Vaginal Health?

When it comes to supporting vaginal health, Lemme Purr may not be the best option. Its primary probiotic strain, Bacillus coagulans, isn’t among the top performers in this category. In fact, research consistently points to Lactobacillus strains—particularly those like Lactobacillus acidophilus—as far more effective at maintaining a healthy vaginal environment.

Lactobacillus bacteria work by producing lactic acid, which keeps the vaginal pH acidic. This makes it difficult for harmful bacteria and yeast to thrive. Several studies back this up. For example, one trial found that women using Lactobacillus acidophilus vaginal tablets—with doses ranging from 100 million to 1 billion CFUs—had higher cure rates for bacterial vaginosis than those using a placebo. Even smaller oral doses, around 10 million CFUs daily, showed some promise in other trials. Another study found that women who used a Lactobacillus suppository after antifungal treatment were slightly less likely to experience a return of yeast infections.

But here’s the key detail: most of these positive outcomes came from vaginal use of probiotics, not oral supplements. That’s an important distinction. While oral probiotics containing Lactobacillus may still help in some cases, their impact on vaginal health tends to be much weaker. Some blends with Lactobacillus acidophilus may lower the risk of bacterial vaginosis, but because they include multiple strains, it’s hard to tell which one is doing the job. And in at least one clinical trial, healthy women who took Lactobacillus acidophilus orally didn’t show any boost in vaginal bacteria at all.

So, are oral probiotics useless for vaginal health? Not necessarily—but their effectiveness is limited. The theory is that beneficial bacteria could travel from the digestive tract to the vaginal area, but in reality, this route seems far less effective than direct application through a vaginal probiotic suppository.

Among oral options, one specific combination has shown results: Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. This duo has been linked to a lower risk of urinary tract infections (UTIs). For example, postmenopausal women who took these strains daily for a year had fewer UTIs. It’s one of the few oral probiotic combos with proven vaginal and urinary health benefits.

Unfortunately, Lemme Purr doesn’t contain the GR-1 and RC-14 strains, likely because they can’t survive the gummy-making process. Instead, it sticks with Bacillus coagulans, which may support digestion, but isn’t strongly backed for vaginal health. And even when it comes to gut benefits, there’s a caveat.

Most of the positive research on Bacillus coagulans and other probiotics comes from capsules, powders, or fermented foods—not gummies. Clinical studies on gummy probiotics are still rare. In one small trial, undernourished infants were given Lactobacillus plantarum in gummy form and showed slight improvements in gut health. Another study gave healthy adults a gummy with Bacillus coagulans and found the bacteria survived digestion and remained in the gut for several weeks. While promising, these findings don’t prove that gummy probiotics like Lemme Purr can treat digestive issues like IBS or support vaginal health.

What’s the Better Option for Vaginal Health?

If your main goal is to improve or maintain vaginal health, your best bet is likely a vaginal probiotic suppository with clinically supported Lactobacillus strains. These deliver bacteria directly where they’re needed and are far more effective than oral routes. But if you prefer an oral supplement for convenience, look for one that contains the GR-1 and RC-14 strains, which have shown benefits for both vaginal microbiome balance and UTI prevention.

In short, while Lemme Purr may offer mild digestive support, it’s not the most effective choice for vaginal health. For targeted benefits, especially if you’re dealing with issues like bacterial vaginosis, yeast infections, or UTIs, a more strain-specific probiotic—especially in suppository form—will likely serve you better.

Overall rating

Lemme-Purr-review-overall-summary-rating — Overall rating Lemme Purr review summary

When it comes to improving vaginal health, I’m giving it a D. While Bacillus coagulans may have some digestive uses, the evidence behind it for vaginal health is far too weak.

Rating it by cost, I’m giving it a C. It’s moderately expensive for a generic gummy probiotic.

Rating it for safety, I’m giving it a B. The strains used are unlikely to be of much cause for concern.

Overall rating, I’m giving a D. I would not recommend it at all.

Top alternatives to URO Vaginal Probiotics

Probiotic (Align) – 1 cap / day
Probiotic (Culturelle) – 1 cap / day
Probiotic (generic) – 1 cap / day
Probiotic (GR-1/RC-14) – 1 cap / day
Probiotic (vaginal) – 1 cap / day

Learn more about

Citations

Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN. 2020 Oct;39:53-60. doi: 10.1016/j.clnesp.2020.06.020. Epub 2020 Jul 24. PMID: 32859329.

Anaya-Loyola MA, Enciso-Moreno JA, López-Ramos JE, García-Marín G, Orozco Álvarez MY, Vega-García AM, Mosqueda J, García-Gutiérrez DG, Keller D, Pérez-Ramírez IF. Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Res Int. 2019 Nov;125:108567. doi: 10.1016/j.foodres.2019.108567. Epub 2019 Jul 21. PMID: 31554075.

Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012 May 14;172(9):704-12. doi: 10.1001/archinternmed.2012.777. PMID: 22782199.

Coste I, Judlin P, Lepargneur JP, Bou-Antoun S. Safety and efficacy of an intravaginal prebiotic gel in the prevention of recurrent bacterial vaginosis: a randomized double-blind study. Obstet Gynecol Int. 2012;2012:147867. doi: 10.1155/2012/147867. Epub 2012 Dec 18. PMID: 23316237; PMCID: PMC3536433.

Hallén A, Jarstrand C, Påhlson C. Treatment of bacterial vaginosis with lactobacilli. Sex Transm Dis. 1992 May-Jun;19(3):146-8. doi: 10.1097/00007435-199205000-00007. PMID: 1523530.

Horosheva et al. Efficacy of Bacillus probiotics in prevention of antibiotic‐associated diarrhoea: a randomized, double‐blind, placebo‐controlled clinical trial. JMM Case Reports. Vol 1, Iss. 3. Doi: 10.1099/jmmcr.0.004036

Kamil et al. Development of probiotic gummy candy using the indigenous Lactobacillus plantarum Dad-13 strain; evaluation of its gastrointestinal resistance and shelflife prediction. October 2021Food Research 5(5):265-273. DOI:10.26656/fr.2017.5(5).731

Kamil RZ, Murdiati A, Juffrie M, Rahayu ES. Gut Microbiota Modulation of Moderate Undernutrition in Infants through Gummy Lactobacillus plantarum Dad-13 Consumption: A Randomized Double-Blind Controlled Trial. Nutrients. 2022 Mar 1;14(5):1049. doi: 10.3390/nu14051049. PMID: 35268024; PMCID: PMC8912314.

Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008 Jan 15;8:3. doi: 10.1186/1472-6874-8-3. PMID: 18197974; PMCID: PMC3225869.

Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010 Jan 12;10:1. doi: 10.1186/1472-6882-10-1. PMID: 20067641; PMCID: PMC2826289.

Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study. J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S102-5. doi: 10.1097/MCG.0000000000000225. PMID: 25291115.

Parent D, Bossens M, Bayot D, Kirkpatrick C, Graf F, Wilkinson FE, Kaiser RR. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung. 1996 Jan;46(1):68-73. PMID: 8821521.

Perotti S, Mantegazza G, Pierallini E, Kirika N, Duncan R, Telesca N, Sarrica A, Guglielmetti S. Human in vivo assessment of the survival and germination of Heyndrickxia coagulans SNZ1969 spores delivered via gummy candies. Curr Res Food Sci. 2024 Jun 18;9:100793. doi: 10.1016/j.crfs.2024.100793. PMID: 39071473; PMCID: PMC11278553.

Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, Garland S. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ. 2004 Sep 4;329(7465):548. doi: 10.1136/bmj.38210.494977.DE. Epub 2004 Aug 27. PMID: 15333452; PMCID: PMC516107.

Rani, V.U. & Rao, S.R. & Grisha, P. & Sharma, A.V. & Usha, M.S.. (2017). The efficacy of probiotic b. Coagulans (snz-1969) tablets in the treatment of recurrent bacterial vaginosis. International Journal of Probiotics and Prebiotics. 12. 175-182.

Ratna Sudha M, Yelikar KA, Deshpande S. Clinical Study of Bacillus coagulans Unique IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis. Indian J Microbiol. 2012 Sep;52(3):396-9. doi: 10.1007/s12088-011-0233-z. Epub 2011 Sep 23. PMID: 23997330; PMCID: PMC3460128.

Reznichenko H, Henyk N, Maliuk V, Khyzhnyak T, Tynna Y, Filipiuk I, Veresniuk N, Zubrytska L, Quintens J, Richir K, Gerasymov S. Oral Intake of Lactobacilli Can Be Helpful in Symptomatic Bacterial Vaginosis: A Randomized Clinical Study. J Low Genit Tract Dis. 2020 Jul;24(3):284-289. doi: 10.1097/LGT.0000000000000518. PMID: 32091443.

Shalev E, Battino S, Weiner E, Colodner R, Keness Y. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med. 1996 Nov-Dec;5(10):593-6. doi: 10.1001/archfami.5.10.593. PMID: 8930233.

Spaggiari L, Ardizzoni A, Pedretti N, Iseppi R, Sabia C, Russo R, Kenno S, De Seta F, Pericolini E. Bacillus coagulans LMG S-24828 Impairs Candida Virulence and Protects Vaginal Epithelial Cells against Candida Infection In Vitro. Microorganisms. 2024 Aug 10;12(8):1634. doi: 10.3390/microorganisms12081634. PMID: 39203476; PMCID: PMC11356316.

Zhang Y, Lyu J, Ge L, Huang L, Peng Z, Liang Y, Zhang X, Fan S. Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an Adjunctive Treatment for Bacterial Vaginosis Do Not Increase the Cure Rate in a Chinese Cohort: A Prospective, Parallel-Group, Randomized, Controlled Study. Front Cell Infect Microbiol. 2021 Jul 6;11:669901. doi: 10.3389/fcimb.2021.669901. PMID: 34295831; PMCID: PMC8291149.